Literature DB >> 27517227

Biliary excretion and enterohepatic recirculation of practolol in man.

S G Carruthers1,2, J G Kelly1,2, G W Johnson1,2, D G McDevitt1,2.   

Abstract

The elimination of practolol in bile was studied in six patients who received a single oral dose of 400 mg within six days of undergoing biliary surgery. Bile collections were made from a T-tube drain left in the common bile duct after removal of multiple biliary calculi. There was wide variation in the concentration of practolol in bile and in the total amount of practolol excreted in bile during the 48 hour period after dosage. Two patients excreted 23 per cent and 41 per cent of the 400 mg dose in bile, whereas the excretion in the other four patients was only one per cent to four per cent of the oral dose. The mean urinary excretion of practolol in 48 hours was 74.2±S.E. 8.4 per cent of the ingested dose, and the total elimination (biliary plus urinary) was 86.5±S.E. 7.6 per cent. The total elimination ranged from 92 per cent to 105 per cent in four of the patients. The mean elimination half-life of practolol in blood was 6.4±S.E. 0.5 hours. This was significantly less than the half-life in normal subjects receiving the same practolol dose. Since complete or near-complete urinary excretion of practolol is found in normal subjects, the presence of large amounts of drug in the bile suggests that enterohepatic recirculation of the drug occurred in some of the patients at least. This is a possible explanation of the shortened half-life in these patients in whom drug was being removed with bile. The four patients with low excretion of practolol in bile were receiving other drugs at the time of the study. These included nitrazepam, diazepam and tetracycline which are known to have substantial biliary elimination either in animals or man. It is suggested that competition for biliary excretion may have occurred and this may represent a drug interaction of possible clinical significance.

Entities:  

Year:  1976        PMID: 27517227     DOI: 10.1007/BF02938943

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  11 in total

1.  Biliary excretion of diazepam and its metabolites in man.

Authors:  R Sellman; J Kanto; J Pekkarinen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975-09

2.  Further studies on the metabolic fate of chloral hydrate and trichloroethanol.

Authors:  A H OWENS; E K MARSHALL
Journal:  Bull Johns Hopkins Hosp       Date:  1955-10

Review 3.  Biliary excretion and hepatotoxicity of contraceptive steroids.

Authors:  R L Smith
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1974

4.  The metabolism and distribution of the selective adrenergic beta blocking agent, practolol.

Authors:  B Scales; M B Cosgrove
Journal:  J Pharmacol Exp Ther       Date:  1970-11       Impact factor: 4.030

5.  Blood levels of practolol following intravenous administration.

Authors:  W H Aellig; B N Prichard; B Scales
Journal:  Br J Pharmacol       Date:  1970-11       Impact factor: 8.739

6.  Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man.

Authors:  G Bodem; C A Chidsey
Journal:  Clin Pharmacol Ther       Date:  1973 Jan-Feb       Impact factor: 6.875

7.  Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate.

Authors:  S G Carruthers; J G Kelly; D G McDevitt; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

8.  Delayed recovery from a sedative: correlation of the plasma levels of diazepam with clinical effects after oral and intravenous administration.

Authors:  E S Baird; D M Hailey
Journal:  Br J Anaesth       Date:  1972-08       Impact factor: 9.166

9.  Effect of a new adrenergic beta-blocking agent (ICI 50,172) on heart rate in relation to its blood levels.

Authors:  J D Fitzgerald; B Scales
Journal:  Int Z Klin Pharmakol Ther Toxikol       Date:  1968

10.  Excretion of radioactive digitoxin by the dog.

Authors:  B G Katzung; F H Meyers
Journal:  J Pharmacol Exp Ther       Date:  1965-08       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.